Studie

A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation

Erkrankungsgruppe:

Begleittherapie

Organsystem:

Blut

Stadium:

Therapierefraktär

Standort:

Essen

EudraCT:

2016-002584-33

Prüfplan-Code:

CINC424C2301

Phase:

III

Prüfsubstanz:

Ruxolitinib

Sponsor:

Novartis Pharma Services AG